secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2025-12-02T23:59:59+00:00
Accession:  0001730463-25-000095
Event type: leadership
Sentiment:  positive
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus appoints former BioNTech CSO Ryan Richardson to Board
-------------------------------------------------------------

- Ryan Richardson appointed as Class I director effective Dec 1, 2025; served as BioNTech CSO (2018–2025).
- Will receive £33,000 annual retainer and initial option grant for 80,000 ADSs at $1.41/ADS, vesting over 36 months.
- Richardson led BioNTech's corporate strategy, capital markets, and multiple M&A deals.
- Prior roles include Executive Director at J.P. Morgan Healthcare Investment Banking (2011–2018).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000173046325000095/0001730463-25-000095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000173046325000095/autl-20251201.htm
  HTML page:      https://secwatch.observer/filing/0001730463-25-000095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer